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Abstract

Patients with Parkinson disease are prescribed dopamine agonists such as pramipexole to
improve motor symptoms. Several studies have found that patients taking dopaminergic
medication develop impulse control disorders. In contrast, other studies suggest that some
behaviors become less impulsive with pramipexole. We evaluated the performance of 20 young,
healthy participants who received pramipexole (0.5 mg) and 20 participants who received
placebo, on the Go/No-Go, the Stop Signal Task, and the Balloon Analogue Risk Task. We
found that the pramipexole group had more timed out Go trials on the Go/No-Go task than the
placebo group, suggesting reduced motor impulsivity. There were no differences between the
two groups’ performance on the other impulsivity tasks. This pattern of results is in line with the
theory that impulsivity consists of a motor and a cognitive aspect, and that pramipexole might
decrease motor, but not cognitive impulsivity.
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Chapter 1: Introduction
1.0 Literature review
Parkinson’s disease (PD) is a progressive neurodegenerative disorder in which dopamineproducing neurons degenerate in the substantia nigra pars compacta (SNpc), and to a much lesser
extent in the neighbouring ventral tegmental area (VTA), leading to motor and cognitive
impairments. The hallmark motor symptoms of PD include tremor at rest, rigidity (of limbs and
the trunk), and bradykinesia (slowness of movement; Dauer & Przedborski, 2003; Jankovic,
2008). Impairments in cognition, specifically in frontostriatal functions (such as learning,
memory, and executive functions) are also recognized as an indisputable feature of PD (Aarsland
& Kurz, 2010; Barone et al., 2011). PD is predominantly an age-associated disorder with a sharp
increase in prevalence after the age of 60, although there are cases of PD with onset before 50
(de Lau & Breteler, 2006). The estimated prevalence of PD in adults older than 60 is around 1%,
with some studies finding rates closer to 2– 3%, making it the second most common ageassociated disorder (de Lau & Breteler, 2006). The etiology of PD is not fully understood and
there is no cure for the disease. Motor symptoms are well mitigated by medication, whereas nonmotor symptoms, which present more varied deficits and do not respond as well to medication,
tend to be the major cause of impairments and institutionalization (Aarsland, Larsen, Tandberg,
& Laake, 2000; Aarsland, Zaccai, & Brayne, 2005; Dauer & Przedborski, 2003; Halliday,
Leverenz, Schneider, & Adler, 2014; Seppi et al., 2011). Non-motor deficits in PD are complex
and likely have several causes, including PD pathology, side effects of dopaminergic medication,
and adverse interactions between PD pathology and medication effects (Aarsland, Brønnick,
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Larsen, Tysnes, & Alves, 2009; Bosboom, Stoffers, & Wolters, 2004; Caballol, Martí, & Tolosa,
2007; Rowe et al., 2008; Seppi et al., 2011).
1.1 Pathophysiology of PD
Physiologically, PD is marked by a selective and rapid degeneration of dopaminergic cells
projecting to the striatum from the SNpc. The striatum comprises the caudate nucleus, the
putamen, and the nucleus accumbens (Obeso et al., 2008; Voorn, Vanderschuren, Groenewegen,
Robbins, & Pennartz, 2004). The striatum is often described in terms of a ventral and a dorsal
portion – the dorsal striatum (DS), and the ventral striatum (VS). Although no clear boundaries
exist separating the DS and the VS, the areas tend to be subdivided along relatively consistent
demarcations (see Figure 1), usually setting the boundary between the dorsal parts of the caudate
and putamen (collectively called the DS), and the ventral portion of the putamen as well as the
nucleus accumbens (collectively called the VS; Voorn et al., 2004). The division is in large part
supported by behavioral and cognitive differences in the functioning of these different areas
(Obeso et al., 2008; Voorn et al., 2004). Neuroanatomically, there are also subtle
cytoarchitectural changes along different points of the striatum, although there is no clear
anatomical difference marking a boundary between the DS and VS (Voorn et al., 2004).
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Figure 1: Commonly accepted subdivision of the striatum into the DS and the VS. Adapted
from Telzer, 2016.

Cells in the SNpc, which project to the DS, deteriorate much more rapidly than cells in the VTA,
which project to the VS (Kish, Shannak, & Hornykiewicz, 1988). This results in a greater overall
loss of dopamine in the SNpc and the DS and their afferents, compared to the VTA and the VS.
This dopaminergic deficiency in the SNpc-DS pathway produces the cardinal motor symptoms
of PD including tremor, rigidity, and bradykinesia (Dauer & Przedborski, 2003; Jankovic, 2008).
Rather than being responsible for the execution of motor commands per se, the SNpc-DS system
is involved in the selection of actions (Balleine, Delgado, & Hikosaka, 2007). Additionally, the
SNpc-DS system is involved in procedural learning and stimulus-response learning, for example,
when learning a new motor sequence or a response to a new stimulus (Packard & Knowlton,
3

2002; White & McDonald, 2002). The DS is also involved in the performance of less habitual
and more considered actions (Ali, Green, Kherif, Devlin, & Price, 2009; Benke, Delazer, Bartha,
& Auer, 2003; Cameron, Watanabe, Pari, & Munoz, 2010; MacDonald, Seergobin, Tamjeedi, &
Owen, 2014; Macdonald & Monchi, 2011; Mestres-Missé, Turner, & Friederici, 2012;
Robertson, Hiebert, Seergobin, Owen, & MacDonald, 2015). The medial part of the DS has also
been shown to affect inhibitory control of motor actions (Eagle & Robbins, 2003), which is
required to stop or prevent an action from being executed.

Similarly, the VTA-VS system can be thought of as a mediator of motor behaviors, but more
specifically in the context of reward and reinforcement-based behaviors (Cardinal, Parkinson,
Hall, & Everitt, 2002; McBride, Murphy, & Ikemoto, 1999). Reversal learning is mediated by
the VTA-VS system, which involves the extinction of previously reinforced behaviors (Cools,
Clark, Owen, & Robbins, 2002). Evidence also suggests its involvement in spatial learning
(Setlow, 1997). In summary, both the DS and the VS are involved in a range of cognitive
functions, thus their dysfunction can contribute to non-motor impairments in PD (Atallah,
Lopez-Paniagua, Rudy, & O’Reilly, 2007; Dirnberger & Jahanshahi, 2013; Grahn, Parkinson, &
Owen, 2009; Nagano-Saito, Martinu, & Monchi, 2014).

Ultimately, the striatum, which receives inputs from nearly all areas of the cortex, influences
actions through its inhibition or disinhibition of the thalamus, which then feeds back into the
initial region of the cortex where the signal originated (Obeso et al., 2008). The striatum is
predominantly populated by medium spiny neurons, which send inhibitory GABAergic signals
along two main pathways known as the direct pathway and the indirect pathway. The direct
4

pathway functions through the activation of D1 dopaminergic receptors, and begins at the
striatum, making inhibitory connections with the globus pallidus pars interna (GPi). The GPi
forms inhibitory connections with the thalamus, so inhibition of the GPi actually disinhibits the
thalamus. As a result, stimulation of the direct pathway via D1 receptors leads to a disinhibition
of the thalamus, which then sends excitatory feedback amplifying the original signal. The
indirect pathway contains cells with D2 receptors. The striatum projects inhibitory connections
to the globus pallidus pars externa (GPe), which projects inhibitory connections to the
subthalamic nucleus. The subthalamic nucleus forms excitatory connections with the GPi, which,
as previously discussed, inhibits the thalamus. Thus, stimulation of the indirect pathway inhibits
the GPe, which disinhibits the subthalamic nucleus. The subthalamic nucleus then excites the
GPi, and the GPi inhibits the thalamus. The net result of stimulation of the indirect pathway is
the inhibition of the thalamus, and a dampening of the original signal (Obeso et al., 2008).
1.2 Medication to treat motor symptoms
Although there is no cure for PD, medication sufficiently alleviates the motor symptoms caused
by dopamine deficiency in the SNpc, especially in the earlier stages of disease. Medication to treat
PD, which primarily acts on dopaminergic cells and receptors, is titrated with the aim of restoring
dopamine to the deficient SNpc-DS system. The two most effective drug types used to treat PD
are the dopamine precursor L-3,4-dihydroxyphenylalanine (levodopa), and dopamine agonists
(such as pramipexole, ropinirole, rotigotine, and apomorphine; Connolly & Lang, 2014).
Levodopa is a dopamine precursor that leads to the production of dopamine. In the striatum, it acts
presynaptically on dopaminergic cells and is converted to dopamine, making up for the decreased
dopamine from the SNpc (Lang & Lees, 2002). In contrast, dopamine agonists act post-
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synaptically, by attaching to, and activating dopamine receptors directly (Brooks, 2000; Quinn,
1995). The actions of both types of drugs cause a net increase of activated dopaminergic receptors
in the striatum However, the acute dopamine activity caused by the drugs is markedly different
from the consistent release of low doses of dopamine that occurs in an unimpaired dopaminergic
system (Lang & Lees, 2002). These drugs are currently titrated to treat the motor symptoms of PD
resulting from the deficiency in the SNpc-DS system (Connolly & Lang, 2014), with little regard
for the effects on more complex behaviors and cognition that are also mediated by the striatum.

Both drug types are associated with the development of behavioral and cognitive complications.
Research shows that whereas some functions improve when patients are on medication, others
become worse (Cools, Barker, Sahakian, & Robbins, 2001; MacDonald et al., 2011; Macdonald
& Monchi, 2011). Continued use of levodopa leads to levodopa-induced dyskinesia (LID), a
condition marked by jerky, involuntary and purposeless movements that usually appear at the
time levodopa effects are at their peak (Ahlskog & Muenter, 2001; Carta, Carlsson, Kirik, &
Bjorklund, 2007). Review studies estimate that over the course of 4-6 years of treatment, around
40% of patients develop LID, and the prevalence increases to between 60-89% by 10 years of
treatment (Ahlskog & Muenter, 2001; Fabbrini, Brotchie, Grandas, Nomoto, & Goetz, 2007;
Zesiewicz, Sullivan, & Hauser, 2007). To treat LID, patients are commonly given lower doses of
levodopa, but this increases the duration of the OFF period (i.e. when the anti-parkinsonian
effects of levodopa wear off and motor symptoms worsen) and makes the disease more difficult
to manage. Treatment with dopamine agonists leads to fewer instances of dyskinesia than
treatment with levodopa (Parkinson Study Group, 2000), so early treatment with dopamine
agonists is preferable.
6

However, the prolonged use of dopamine agonists, such as pramipexole, has been associated with
the development of impulse control disorders (ICDs) in patients with PD (Aarsland & Kurz, 2010;
Burdick et al., 2014; Pontone, Williams, Bassett, & Marsh, 2006). ICDs are characterized by the
occurrence of impulsive actions and behaviors such as gambling, binge eating, hyper-sexuality,
and uncontrollable spending. Weintraub and colleagues, (2010) found that patients taking
dopamine agonists are at a 2 – 3.5 times greater risk of developing an ICD, but suggested that
additional demographic and clinical factors may influence the development of ICDs.

Most studies investigating the effects of dopaminergic medication on cognition and impulsivity
have been conducted on PD patients (Macdonald & Monchi, 2011; Poletti & Bonuccelli, 2013),
which presents difficulty in interpreting the effects of dopaminergic medication. Typical PD
samples vary widely in terms of age, disease duration and time of onset, as well as overall disease
severity. To better understand whether the association between dopamine agonists and the
development of ICDs is due to the medication, due to an interaction between medication and PD
pathology, or due to an interaction with other demographic factors associated with PD, it is
necessary to investigate the effects of the medication in isolation from these other confounding
variables.

Additionally, the cognitive pathology of PD patients is complex. First, there is strong evidence
that some cognitive deficits result from striatal dopamine deficiency (Barone et al., 2011;
Bosboom et al., 2004; Caballol et al., 2007). Second, in addition to dopaminergic pathways,
dysregulation in cholinergic (Bohnen et al., 2006; Gilman, 2010), serotonergic (Huot, Fox, &
7

Brotchie, 2011; Ye et al., 2014) and noradrenergic (Del Tredici & Braak, 2013; Vazey & AstonJones, 2012; Weintraub, 2010) pathways appears to also contribute to cognitive deficits in PD.
Dopamine sensitization following prolonged use of dopaminergic medication (Fenu, Wardas, &
Morelli, 2009) could further complicate the relationship between dopamine agonists in PD and
the appearance of ICDs. There is also evidence showing that patients with PD have reduced
levels of the dopamine transporter DAT, which regulates synaptic dopamine levels, and this
decrease could exacerbate the effects of dopamine to pathological levels (Harrington, Augood,
Kingsbury, Foster, & Emson, 1996; Kalia & Lang, 2015; Kordower et al., 2013; Voon, 2009).
Thus, with many variables potentially affecting cognition in PD, any effects of medication are
difficult to interpret.

Dopamine agonists are also increasingly prescribed outside the context of PD, so it is important
to understand the effects of this medication in isolation from PD. Individuals with restless leg
syndrome (RLS; Comella, 2002; Högl, Paulus, Clarenbach, & Trenkwalder, 2006; Hornyak,
Scholz, Kohnen, & Bengel, 2014; Trenkwalder, Hening, Montagna, & Oertel, 2008; Zintzaras,
Kitsios, Papathanasiou, & Konitsiotis, 2010) and in some cases dystonia (Cloud & Jinnah, 2010;
Jankovic, 2013) are treated with dopamine agonists. Additionally, the use of dopamine agonists
is being investigated in the treatment of depression (Goto, Yoshimura, Kakihara, & Shinkai,
2006; Hori & Kunugi, 2012, 2013; Howland, 2012; Papakostas, 2006) , drug addiction (Carroll,
Howell, & Kuhar, 1999; Streeter, Hennen, Ke, & Jensen, 2005) and to address withdrawal
symptoms (Makhinson & Gomez-Makhinson, 2014; Ohmura, Jutkiewicz, Zhang, & Domino,
2011). Therefore, investigating the effects of dopamine agonists on impulsivity in healthy

8

controls is necessary to avoid the many factors that might interact with the medication when
studied in clinical populations.
1.3 Pramipexole effects on impulsivity
Pramipexole is a nonergot dopamine agonist, which unlike levodopa does not promote the
production of dopamine, but directly stimulates dopaminergic receptors. Research in rats
(Piercey, Walker, Feldpausch, & Camacho-Ochoa, 1996) and humans (Gerlach et al., 2003) has
shown that pramipexole has a high binding affinity to dopaminergic receptors in the striatum.
Pramipexole is an agonist on the D2 subfamily of receptors. This includes the D2, D3, and D4
subtypes (Missale, Nash, Robinson, Jaber, & Caron, 1998). It binds primarily to the D2/D3
dopamine receptors and is used to treat PD as well as restless-leg-syndrome (Ferini-Strambi et
al., 2008; Montplaisir, Nicolas, Denesle, & Gomez-Mancilla, 1999; Reichmann, Brecht, Koster,
Kraus, & Lemke, 2003). Pramipexole’s binding of the D2 receptors has been considered
responsible for the improvement in motor symptoms in PD, whereas its binding to D3 receptors
might be responsible for some improvement in depressive symptoms (Guttman & Jaskolka,
2001).

Studies investigating the effects of pramipexole on impulsivity have yielded results suggesting it
increases some aspects of impulsivity and decreases others. Experiments with rats have
repeatedly demonstrated that single doses of pramipexole increase impulsive, gambling-like
behavior in reward related tasks (Holtz, Tedford, Persons, Grasso, & Napier, 2016; Johnson,
Madden, Brewer, Pinkston, & Fowler, 2011; Madden, Johnson, Brewer, Pinkston, & Fowler,
2010). In human studies, experiments have demonstrated that a single dose of pramipexole
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affects the reward network. Participants show a preference for riskier rewards and a decrease in
brain activity associated with the attainment of a reward (Riba, Krämer, Heldmann, Richter, &
Münte, 2008). Another neuroimaging experiment showed that pramipexole increased the
connectivity between the nucleus accumbens and the anterior insula, but decreased the
connectivity between the nucleus accumbens and the prefrontal cortex (Ye, Hammer, Camara, &
Münte, 2011). In addition to the studies finding an association between pramipexole and ICDs
and impulsivity, these results suggest that pramipexole disrupts reward-related neural pathways,
leading to impulsive behavior.

In contrast, Fera and colleagues (2007) found that PD patients were more accurate on the
incongruent condition of a Stroop task when they were on dopaminergic medication than when
they were off medication, suggesting better cognitive control in the face of ambiguity.
Specifically, in the modified Stroop task, patients had to select (via button press) one of four
color words (green, blue, red, yellow) describing either the color of a square presented in the
centre (Congruent condition) or the color of a color word printed in different ink in the centre of
the screen (e.g. the word ‘Blue’ printed in red ink). In another study, Caillava-Santos and
colleagues (2015) found that patients with PD were more quick to respond to incongruent trials
of a Stroop task on medication compared to when they were off medication. In an experiment by
Hiebert and colleagues (2014) PD patients had to learn stimulus-response associations that were
either congruent or incongruent spatially. Patients responded faster to congruent and incongruent
trials when they were off medication compared to when they were on medication, which is
evidence of attenuated impulsivity by dopaminergic medication. An experiment by van Wouwe
and colleagues (2016) elegantly dissociated impulse capture from impulse control in PD patients
10

on and off medication by employing the Dual Process Activation Suppression framework to
examine performance on a Simon task. In the context of the framework, inhibiting an impulse
consists of two processes: 1) impulse capture, which is the initial activation and initiation of a
response to a stimulus and 2) reactive impulse control, which acts to prevent and inhibit an
activated impulsive response. The theory states that in conflicting situations an incorrect
impulsive response is initiated through a direct processing route, and that inhibition of this
impulse is carried out through a deliberate, goal-oriented processing route (Ridderinkhof, 2002).
The framework also provides analytical tools that allow to examine the distribution of responses
and separately quantify the strength of impulse capture and of reactive impulse control. In the
experiment, which employed the Simon task, participants had to press a button with their right or
left hand in response to a colored circle appearing on the left or right side of a screen. A blue
circle required a response with the left hand, and a green circle, with the right hand. The task
consisted of Congruent trials (e.g. a blue circle, requiring a left-hand response, appearing on the
left side) and Noncongruent trials (a blue circle appearing on the right side). The distribution of
responses to the Simon task ranges from quick impulsive and incorrect responses (a measure of
impulse capture) to slow, deliberate responses (when impulse control processes have built up).
The results indicated that PD patients had better impulse control on medication than off, and that
impulse capture was not affected by medication. Thus, only the ability to control the execution of
an impulsive response was affected by the dopaminergic medication. In summary, it appears that
dopaminergic medication slows down or attenuates some impulsive processes in patients with
PD, while also exacerbating impulsivity in other, more complex behaviors that are rewarddependent.
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An explanation of the seemingly contradictory effects of pramipexole on impulsivity can be
offered by looking at impulsivity as a multifaceted phenomenon. Impulsivity is a complex
construct entailing many different aspects of thought and behavior. Broadly, impulsivity can be
defined as the inability to inhibit premature or pre-potent actions (i.e. actions that have
previously been reinforced and become primed), along with a tendency towards risky or less
calculated choices (Dalley, Everitt, & Robbins, 2011). Thus, it is clear that impulsivity involves
multiple, possibly distinct behaviors.

Impulsivity can be divided into two domains: motor impulsivity and cognitive impulsivity
(Antonelli, Ray, & Strafella, 2011). A principal component analysis (PCA) on 11 of the most
common questionnaires and tasks used to measure impulsivity, including the Go/No-Go task
(GNG), the Stop Signal Task (SST), and the Kirby Temporal Discounting task, supports a
division of impulsivity into multiple aspects (Nombela, Rittman, Robbins, & Rowe, 2014). The
analysis revealed 4 components, which were classified by the authors as follows: 1) Interference
and response conflict in decision making, 2) Motor response inhibition, 3) Delay aversion and
time estimation, 4) Temporal discounting. The components were dissociable and correlated with
distinct demographic measures.

A larger PCA by Caswell and colleagues (2015) using a sample of healthy young adults further
demonstrated that impulsivity is a heterogeneous construct. Specifically, their aim was to test
whether impulsivity was composed of different subtypes, including motor-impulsivity, temporalimpulsivity, and reflective-impulsivity. They also aimed to test whether tasks that are used
interchangeably to assess subtypes of impulsivity have shared factor loadings and correlations.
12

The authors tested 160 participants on 10 behavioral and one self-report measure of impulsivity.
A PCA revealed four components as well, though the authors did not explicitly classify each
component. However, component 1 had a high loading of the SST, which is likely to be the
motor-impulsivity component. Curiously, the GNG task, another classic impulsivity measure, did
not load on the same component. Component 2 had a high loading of the Information Sampling
Task and the Matching Familiar Figures Task, leading the authors to classify it as a reflectiveimpulsivity component. Component 3 had a high loading of the Immediate Memory Task.
Component 4 had a high loading of the Delay Discounting Task and the Monetary Choice
Questionnaire, which was classified as the temporal-impulsivity component. The effects of
pramipexole on impulsivity therefore are likely a combination of its influence on multiple
aspects, cognitive and motor. It appears that pramipexole might increase some aspects of
cognitive impulsivity (i.e. risk taking) but decrease other aspects, such as motor impulsivity.
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1.4 Measures of impulsivity
Over the years, the complex and multi-faceted construct of impulsivity has been measured by a
variety of behavioral tasks (See Figure 2).

Figure 2: Multiple aspects of impulsivity and commonly used impulsivity tasks. Adapted from
Winstanley, Olausson, Taylor, & Jentsch, (2010).

The GNG task is a common measure of impulsivity and motor control, because it requires the
inhibition of a highly primed action. In the basic version of a GNG task, participants are told to
press a button as quickly as possible when they see a stimulus appear in the centre of the screen.
Trials proceed in quick succession such that participants are primed to make a quick buttonpress. In this way, the action becomes highly primed and pre-potent. On some trials, a different
stimulus appears, and participants are told that on these trials no action needs to be taken, that is,
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they must withhold the pre-potent impulse to press the button. Behavioral outcome measures on
the GNG can be reaction time (RT) and accuracy (omission errors, commission errors, overall
accuracy, or a ratio of these measures). The GNG task has been used with healthy participants as
well as clinical populations to study impulsivity and differences in cognitive control (Antonelli et
al., 2014; Georgiev, Dirnberger, Wilkinson, Limousin, & Jahanshahi, 2016; Hamidovic, Kang, &
de Wit, 2008; Reynolds, Ortengren, Richards, & de Wit, 2006; Verbruggen & Logan, 2008;
Woltering, Liu, Rokeach, & Tannock, 2013).

We are aware of only one experiment that employed the GNG task in a group of healthy
participants to study the effects of pramipexole on impulsivity. Hamidovic and colleagues (2008)
administered pramipexole or placebo to healthy participants who then performed a GNG task.
They found no effects of pramipexole on any measures of the GNG. However, they employed a
GNG task with a 50:50 Go:NoGo ratio, whereas most GNG experiments use higher Go:NoGo
ratios to ensure the development of a pre-potent response. Thus, it is unlikely that their GNG task
established a pre-potent, impulse-like response in participants.

The SST is a task that also measures impulsivity and the ability to stop a pre-potent action. In the
task, participants choose an appropriate response when presented with a stimulus. Participants
must respond as soon as the stimulus is presented; these are called Go trials. On Stop trials, the
stimulus is followed by a Stop signal. When presented the Stop signal, participants must try to
stop their response on that trial. Difficulty is adjusted by changing the delay between the Go
stimulus and the Stop signal, known as the Stop Signal Delay (SSD). When the SSD is short
(meaning the Stop signal occurs almost simultaneously with the Go stimulus) stopping a
15

response is easier than when the SSD is longer. The accepted theory behind the SST is that of the
‘race model’ (Logan, 1994; Logan, Cowan, & Davis, 1984). The model posits that performance
on the SST reflects a race between a Go process and a Stop process, and that the two are
independent of each other. The two processes compete simultaneously, with each having its own
threshold for completion, and the one that reaches its threshold earlier results in a response (or
lack thereof). The Go process has its own RT distribution, which is easily observed by presenting
participants with stimuli in the absence of Stop-signals. The Stop process is not observable
directly, because its successful execution results in no overt response and is, in fact, indicated by
the absence of a response or action. Thus, the Stop process must be calculated using the RT
distribution of the Go process and the proportion of successfully inhibited Stop trials fitted to
that distribution (Logan et al., 1984). We are not aware of any studies in healthy participants that
investigated the effects of pramipexole on performance of the SST.

The Balloon Analogue Risk Task (BART; Lejuez et al., 2002) is a task that simulates a risktaking situation in the form of a game. In the BART, participants inflate a virtual balloon; the
more pumps they make to inflate the balloon, the more virtual money they earn. They are
presented several balloons, and on each trial they can cash out at any point, or continue inflating
the balloon, until at some predetermined, but unknown and varying pump number, the balloon
explodes and they lose all potential earnings for that balloon. The task has been used to study
impulsivity and risk taking in healthy participants (Chiu et al., 2012; Fukunaga, Brown, & Bogg,
2012; Hamidovic et al., 2008; Rao, Korczykowski, Pluta, Hoang, & Detre, 2008; Reynolds et al.,
2006).
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Impulsivity can also be measured using questionnaires and self report measures. These measures
do not always correlate with results from behavioral tasks, thus it is possible that they capture
different aspects of impulsivity, or that self reported impulsivity and behavioral impulsivity are
dependent on different processes. Among these, the Barratt Impulsiveness Scale (BIS), and the
Sensation Seeking Scale have commonly been used.

Though reports of pramipexole use and the development of impulsivity and ICDs are common in
PD, and there is a clear need to study the effects of the drug in healthy controls to disentangle PD
pathology from medication effects, we are aware of only one other study that investigated
pramipexole’s effects on impulsivity tasks in healthy controls. Hamidovic and colleagues (2008)
conducted a within-subjects study in young, healthy participants who over three sessions
received placebo, 0.25 mg, and 0.5 mg of pramipexole. The participants completed several
questionnaires assessing impulsivity, a simple RT and a two-choice RT task, as well as the GNG,
the BART, a delayed discounting task, and a card perseveration task. The authors found no
effects of pramipexole on any of the impulsivity tasks.
1.5 Aims of the study
In this study, we aimed to explore the effects of a single dose of pramipexole on different aspects
of impulsivity in a sample of young healthy controls. We used a between-subjects, doubleblinded, placebo-controlled design. Both groups completed the three impulsivity tasks (the GNG,
SST, and BART), and measures of impulsivity and impulsivity-related traits using questionnaires
(The BIS and the Sensation Seeking Scale), as well as other questionnaires to assess general
cognition.
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We hypothesized, based on the results appearing in the literature on impulsivity and
dopaminergic medication, that pramipexole will decrease motor impulsivity, measured through
the GNG and SST tasks. On the GNG, this will be evidenced by slower responding, which might
also lead to fewer errors. On the SST, decreased impulsivity might result in a longer SSRT. The
effects of dopamine agonists on reward-dependent impulsivity seem to be opposite, in that
pramipexole should increase risk-taking on the BART, which is a measure of risk-reward and
gambling. This pattern of results would be in line with the theory that pramipexole and dopamine
agonists have opposing effects on different aspects of impulsivity.
Chapter 2: Methods
2.0 Participants
This study was approved by the Health Sciences Research Ethics Board (REB #102018) of the
University of Western Ontario (See
). Participants were recruited from the University of Western Ontario through word of mouth and
advertisements posted around campus. Forty-five young healthy adults were enrolled in the study
(28 females, 17 males). Exclusion criteria were: a history of neurological (e.g., stroke, seizures)
or psychiatric conditions (including clinical depression, hallucinations), family history of more
than one first-degree relative with PD, history of alcohol or drug abuse, any risk factors
associated with taking pramipexole (including taking monoamine oxidase inhibitors, history of
cardiovascular disease, peptic ulcers). All potential participants were pre-screened during a brief
phone interview, and completed an in-person screening form. All participants provided informed
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consent before beginning the experiment in accordance with the Declaration of Helsinki (1991).
All participants were provided with monetary compensation for their time.
2.1 Materials
2.1.1 Health and Demographics and Safety Screening questionnaires
Copies of the ‘Health and Demographics’ and the ‘Safety Screening’ questionnaires are found in
Error! Reference source not found. and Error! Reference source not found.. These questionnaires we
re administered to collect demographic data and ensure that in addition to the safety screening
completed over the phone, there were no contraindications to receiving pramipexole, and that
participants did not meet any exclusion criteria.
2.1.2 Pramipexole and placebo capsules
Participants orally ingested an opaque yellow capsule containing either 0.5 mg of pramipexole
(tablet form, fitted into the capsule) or cornstarch. Capsules were prepared by the investigator and
each capsule was kept inside an individual envelope with a unique code generated by an
independent lab associate, ensuring that the investigator remained blind when giving participants
the capsule. The chosen dose of pramipexole (0.5 mg) is based on dosages used in other studies in
healthy participants (Hamidovic et al., 2008; Pizzagalli et al., 2008; Riba et al., 2008), as this was
the dose shown to produce observable behavioral effects with minimal adverse events. This dose
is commonly prescribed and falls within the therapeutic range. Pramipexole acts primarily on the
D2 family of dopamine receptors, and reaches maximum plasma concentration after approximately
two hours, which is when participants completed the impulsivity tasks. It has a terminal half-life
of eight hours in young adults and about 12 hours in older adults (Putri et al., 2016; Wright, Sisson,
Ichhpurani, & Peters, 1997).
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2.1.3 Questionnaires
The Bond-Lader Visual Analogue Scale (BL-VAS; Bond & Lader, 1974) is a 16-item
questionnaire assessing subjective feelings associated with alertness (alert—drowsy), calmness
(tense—relaxed), and general mood (antagonistic—friendly). We presented participants with
combinations of such opposing adjectives and asked them to place a mark with a pencil on a line
stretching between the two adjectives corresponding to their current feeling. The distance from
each adjective is measured in millimeters and used to calculate a total score for each cluster. See
Error! Reference source not found..

The American National Adult Reading Test (ANART; Nelson, 1982) is a quick, commonly used
measure of verbal intelligence employed in research in multiple populations. Due to its ease of
administration and good overall validity (Bright, Jaldow, & Kopelman, 2002), the ANART was
chosen as a measure of verbal intelligence in this experiment. Participants were instructed to read
out loud a list of 50 words ranging in difficulty in their irregularity of grapheme-phoneme
correspondence (e.g. aisle, hyperbole). They were told to pronounce them correctly, and to make
an attempt even if they are not sure. Total number of correctly pronounced words was used as the
final score. See Error! Reference source not found..

The Montreal Cognitive Assessment (MOCA; Nasreddine et al., 2005) is a measure used to screen
for dementia and mild cognitive impairment. It evaluates basic visuospatial abilities, immediate
and delayed recall as well as working memory, executive functioning and attention, language
abilities, and time and place orientation. It is scored out of 30 points, with scores 26 and greater
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indicating normal cognition. The test is commonly used with older adults. However, it was used
in this experiment with young adults to ensure that groups were well-matched in terms of their
cognitive functions as well as to parallel the procedures employed with older adults to allow for
future between-subject comparisons. See Error! Reference source not found..

The Controlled Oral-Word Association Test (using letters ‘F’, ‘A’, ‘S’; COWAT FAS; Benton,
Hamsher & Silvan, 1994) is a measure of verbal fluency. Participants were asked to generate words
out loud that begin with a given letter of the alphabet. They were allowed 60 seconds to do so,
with the instructions stating that they should avoid proper nouns (e.g., Bob, Boston) and repetitions
of the same word (i.e. perseveration errors) or same word-root with a different ending (e.g., Run,
Running, Runners). The COWAT was administered as a control measure for verbal fluency and
intelligence. See Error! Reference source not found..

The Barratt Impulsiveness Scale- version 11 (BIS; Patton, Stanford, & Barratt, 1995) is a 30-item
questionnaire assessing different aspects of impulsivity. It has been extensively used to study
impulsivity in research and clinical settings (Stanford et al., 2009) and consists of measures of
attentional, motor, and non-planning impulsivity. It is rated on a Likert scale ranging from 1 =
Rarely/Never to 4 = Almost always/Always. The BIS was chosen in this experiment to control for
trait impulsivity that might account for differences between participants’ impulsivity scores on the
behavioral tasks. See Error! Reference source not found..

The Sensation Seeking Scale (Zuckerman, Eysenck, & Eysenck, 1978) consists of 40 pairs of
statements in which the participant must select the statement that most applies to them and their
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beliefs. It is a measure of sensation seeking, composed of scores for Boredom Susceptibility,
Disinhibition, Experience Seeking, and Thrill/Adventure Seeking. See Error! Reference source not f
ound..

The Epworth Sleepiness Scale (Johns, 1991) is a measure of fatigue. Participants were asked to
rate how likely they are to fall asleep/ doze off (0 = “Would never doze” to 3 = ”High chance of
dozing”) in eight different scenarios (e.g. “Sitting and reading” and “Sitting quietly after a lunch
without alcohol”). Total score was used as a final measure of fatigue. We included this measure to
be able to control for trait fatigue. See Error! Reference source not found..

The Oxford Happiness questionnaire (Hills & Argyle, 2002) consists of 29 statements which
participants rate on a 6-point Likert scale from 1 = strongly disagree, to 6 = strongly agree. The
statements assess general well-being (e.g. “I am well satisfied about everything in my life” and “I
am not particularly optimistic about the future). The questionnaire was administered to assess
participants’ trait happiness and well-being to parallel with other experiments and allow for
between-subjects comparisons. See Error! Reference source not found.

The Beck Depression Inventory (BDI; Beck, Steer, & Brown, 1996) was administered as an
additional screening measure for depression. The BDI consists of 21 group of statements about
thoughts and feelings experienced in the past two weeks including the day of testing. Participants
circled the statement that is closest to their feelings/thoughts and the corresponding number. The
total was used as an index of depressive symptoms, with scores of 21 or higher meeting depression
criteria. See Error! Reference source not found..
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The Beck Anxiety Inventory (BAI; Beck & Steer, 1990) measures general anxiety. It asks
participants to rate how much they have been bothered by various common symptoms of anxiety
(e.g. “Wobbliness in legs”, “Face flushed”) during the past week, including the day of the testing.
Participants put a checkmark under options ranging from “Not at all” to “Severely- it bothered me
a lot”, which were then converted to numerical scores and summed. See Error! Reference source n
ot found..

The Starkstein Apathy Scale (SAS; Starkstein et al., 1992) presents participants with 16 statements
assessing apathy. Participants put a check mark under options ranging from “Not at all” to “A lot”
for different statements related to apathy (e.g. “Does anything interest you?” and “Do you need a
push to get started on things?”). The answers were then converted to numerical values and used to
calculate a total apathy score. See Error! Reference source not found..

2.2 Equipment
The computer tasks were performed on a 22.0” monitor (LG Flatron W2242TQ) with a resolution
of 1600 x 900 pixels and a desktop (LG model 73821B-10) using the Windows 7 Professional
operating system. The screen was placed approximately 50 cm away from the participant. A
keyboard (Logitech K120) was used to record participant responses.

2.3 Primary impulsivity measures
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2.3.1 Go/No-Go Task
The GNG is a widely-used task measuring motor impulsivity and the ability to inhibit motor
responses (Antonelli et al., 2014; Ballanger et al., 2009; Kiehl, Liddle, & Hopfinger, 2000; Petit,
Kornreich, Noël, Verbanck, & Campanella, 2012; Rubia et al., 2001; Woltering et al., 2013). The
version we used in the current study, the simple two-stimuli GNG, was chosen due to its ability to
establish a highly pre-potent response in participants, which must be inhibited on certain trials.
During a trial, participants would either see an X, which was the ‘Go’ stimulus, and then press the
spacebar as quickly as possible, or see a K, which was the ‘NoGo’ stimulus to which any response
must be inhibited (i.e. must not press any key). The task consisted of four blocks, each containing
64 trials. Of these trials, 48 were ‘Go’ trials, and 16 were ‘NoGo’ trials, constituting a distribution
of 75% ‘Go’ trials to 25% ‘NoGo’ trials. This distribution was chosen to maximize ‘Go’ response
prepotency, and is consistent with the parameters used in other studies (Boucher et al., 2012; Kiehl
et al., 2000; Liddle, Kiehl, & Smith, 2001; Nieuwenhuis, Yeung, Wildenberg, & Ridderinkhof,
2003).

Trials started with a small grey fixation cross presented in the center of a dark background for 500
milliseconds (ms), followed by a stimulus presented in white, either an X or a K for up to 500 ms.
If participants made a response before the timeout period, an inter-trial interval of 2000 ms
(including the response time) followed, after which the fixation cross for the next trial appeared.
These parameters ensured the development of a quick, pre-potent motor response that would
require inhibitory control to suppress.
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2.3.2 Stop Signal Task
The SST is used to measure control over motor impulsivity, that is, the ability to stop an ongoing
action. The task has been widely used to study impulsivity in various populations (Bedard et al.,
2002; Eagle, Baunez, et al., 2008; Williams, Ponesse, Schachar, Logan, & Tannock, 1999). In the
two-choice version of the task, used in the current experiment, participants were presented one of
two stimuli and needed to press one of two corresponding keys as quickly as possible. In our
experiment, participants were asked to press the ‘Z’ key when they saw the letter ‘X’, and the ‘/’
key when they saw the letter ‘O’. Participants were instructed to press these keys as quickly as
possible after seeing the stimuli – these were the Go trials. On some trials, referred to as Stopsignal trials, an auditory signal would sound after the presentation of the stimulus, which indicated
that participants needed to stop their keypress. The task consisted of 128 trials broken into two
blocks of 64 trials. In each block, 25% of the trials were Stop-signal (16 trials) and the remaining
48 trials were Go trials. Inter-trial interval was set at 2000 ms (including response time). Each trial
started with the presentation of a grey fixation cross in the centre of the screen for 500 ms, followed
by the stimulus which appeared on the screen until a response was recorded or 1250 ms elapsed.
The initial SSD was set at 250 ms, with a staircase adjustment method increasing the SSD by 50
ms after successfully inhibited Stop-signal trials, and decreasing SSD by 50 ms after failed Stopsignal trials. This adjustment was used so that that participants successfully inhibited
approximately 50% of the Stop-signal trials, which is necessary for analysis of the SST.

Participants were told that on some trials the signal would appear shortly after presentation of the
stimulus, which would make stopping their keypress easy, whereas on other trials the signal would
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appear after a slight delay, making stopping more difficult. Participants were encouraged to press
the associated keys as quickly as they could, and were told that when they hear the signal they
should do their best to stop, although on some trials stopping would nearly impossible. That is,
they were told that appropriate performance of the task entails being unable to stop on some trials.
They were explicitly informed that they should not slow their responding on Go trials to reduce
the number of failed stops. This was done in accordance with instructions established previously
(e.g. Logan et al., 1984) meant to encourage participants to provide an accurate and proportional
number of successful and unsuccessful Stop-signal trials.

2.3.3 Balloon Analogue Risk Task
The BART has been previously used in healthy populations to study risk taking. Developed by
Lejuez and colleagues (2002), the BART correlates with multiple established measures of
impulsivity (Lejuez et al., 2002), including self-reports of different dimensions of impulsivity (i.e.
venturesomeness, risk taking, reward seeking) and self-reports of impulsive behavior (i.e. drug
use, alcohol consumption, risky sexual behavior, gambling). Further, the BART accounts for
variance in impulsivity that is not captured by any of the above measures, suggesting it taps into
an understudied or undetected aspect of impulsivity. This makes the BART a suitable task to
capture what is likely a cognitive, reward seeking and risk discounting aspect of impulsivity.

We used a modified version of the original BART task (Lejuez et al., 2002). The version used for
this experiment was modified to be shorter due to pilot data indicating that longer sessions were
less likely to lead to measurable differences. The balloons were presented one at a time in the
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center of the screen, surrounded by a display of the total earned amount, and the current reward in
the temporary bank. Each pump increased the reward in the temporary bank by 5 cents. Participants
could pump the balloon until they decided to collect their reward from that balloon, or until the
balloon exploded. To collect their earnings participants pressed the ‘Z’ key and saw a smiley face
accompanied by sound, indicating a win. Alternatively, if they reached a predetermined point at
which the balloon exploded, known as the breakpoint, they saw a sad face and heard a popping
sound, indicating they lost their current reward in the temporary bank. Participants were not aware
of each balloon’s breakpoint. Across all 30 balloons, and across each block of 10 balloons, the
average breakpoint was 32 pumps. The range of the number of allowed pumps was between 1 and
64 pumps. For the task in the current study, a single randomly generated list of trial breakpoints,
with the constraints noted above, was used for each participant to minimize interactions between
different lists and individual differences of participants.
2.4 Physiological measures
Heart rate (HR) and blood pressure readings (i.e. diastolic and systolic) were taken using an
automated blood pressure cuff (Omron model BP785N). These readings were taken to monitor
participants’ well-being and ensure that they did not experience significant physiological side
effects from pramipexole, and to account for physiological changes across group or related to
medication condition when analyzing behavioral data.
2.5 Procedure
All potential participants were pre-screened during a phone interview before being scheduled for
the experiment. During the phone interview, they were provided information about pramipexole
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and the testing session. The interviewer also went over a safety screening questionnaire to ensure
that potential participants met none of the exclusion criteria for receiving pramipexole.

Upon arrival at the lab, potential participants completed another safety screening questionnaire.
They signed the consent form and completed a health and demographics questionnaire. Following
this, they completed the BL-VAS and their HR and blood pressure were measured, before they
received the capsule. This is referred to as Time 1 (T1). They were provided information about the
double blinding process and were reminded that in the less likely event that they should feel any
side effects during the session, they should inform the experimenter. A timer set to two hours was
started as soon as the participants ingested the capsule. The participants then completed the
ANART, the MOCA, the COWAT FAS, the BIS, the Sensation Seeking Scale, the Epworth
Sleepiness Scale, and the Oxford Happiness Questionnaire. This was followed by practice trials
for each of the computer tasks.

Participants were then given a break with the duration dependent on how much time was left on
the timer until the two hours since capsule ingestion elapsed. During the break, participants could
do anything as long as they remained in the testing room. The investigator came back every 15
minutes to check on the participants and make sure they were feeling fine and were not
experiencing side effects.

After two hours passed since capsule ingestion, when drug concentration was at its peak, HR and
blood pressure measures, as well as BL-VAS ratings, were obtained for a second time. This is
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referred to as Time 2 (T2). Participants then completed the computerized tasks - the GNG,
followed by the BART and the SST.

Task order was the same for all participants to avoid any interactions of task order and differences
in the onset of physiological responses to the drug between participants. After completing all tasks,
HR and blood pressure measures were recorded for one final time. This is referred to as Time 3
(T3). Participants also completed the BL-VAS one further time, were debriefed about the
experiment, and received monetary compensation for their time. An outline of the entire
experimental procedure is shown in Figure 3.

Figure 3: Schematic outline of the experiment.
2.6 Analyses
2.6.1 Time effects of pramipexole
To compare the physiological effects of pramipexole and placebo across time in the experiment,
separate 2 x 3 mixed ANOVAs with Medication (placebo vs. pramipexole) as the between-subjects
variable and Time (T1 vs. T2 vs. T3) as the within-subjects variable were conducted on HR,
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diastolic and systolic blood pressure, and on the BL-VAS ratings. T1 measurements were taken
right after capsule ingestion; T2 measurements were taken two hours after capsule ingestion; T3
measurements were taken approximately 2 hours and 45 minutes after capsule ingestion (after
behavioral tasks).
2.6.2 Go/No-Go Task
A series of independent samples t-tests were conducted on overall GNG accuracy and Go-trial RT.
Overall GNG accuracy is commonly used as a measure of cognitive control and inhibition of prepotent responses. A lower accuracy on the GNG is generally due to higher error rates on NoGo
trials, an indicator of increased impulsivity. Average Go-Trial RT was used as a more direct and
continuous measure of impulsivity in ms as opposed to a binary correct vs. incorrect measure. A
quicker average RT on Go trials would indicate that participants were more predisposed to making
a response, whereas a slower RT would mean participants needed more time to generate or execute
a response, thus were less impulsive.

2.6.3 Stop Signal Task
Stop-signal RT (SSRT), which is the main outcome measure of the task, was calculated by
subtracting the SSD from the average RT (see Logan et al., 1984). An independent samples t-test
was used to compare the average SSRT of the pramipexole and the placebo group. SSRT is a
measure of the unobservable Stop process involved in inhibiting the Go process once a Stopsignal is heard but a response is still ongoing. In order to calculate the SSRT, two conditions
have to be met: 1) The accuracy on Stop trials must be around 50% and 2) mean RT for failed
Stop trials must be shorter than the RT for Go trials (Claassen et al., 2015).
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2.6.4 Balloon Analogue Risk Task
An independent samples t-test was conducted to compare adjusted average number of pumps
between groups. The adjusted average number of pumps is the average number of pumps,
excluding trials on which the balloon popped. This is done because popped trials have a fixed limit
on the number of pumps for each participant, such that even if some participants were to continue
pumping more than others, they would be unable to do so because they were limited by the
balloon’s breakpoint. There exist other variables that can be compared on the BART such as
overall number of pumps, or the number of exploded balloons. To minimize the risk of Type 1
error, analyses on these variables were not performed and the a priori hypothesis was made about
the average adjusted number of pumps. This is a procedure similar to that originally used by Lejuez
and colleagues, (2002). The adjusted average number of pumps is a measure of risky, rewarddependent impulsivity involved in gambling, as the more pumps a person makes, the greater the
reward but the more they risk that the balloon explodes and all earnings for that balloon are lost.

A 2 x 3 mixed ANOVA with Medication as the between-subjects variable and Block (first set of
10 balloons, second 10 balloons, and third 10 balloons) as the within-subjects variable was
conducted on the adjusted average number of pumps. This analysis allows examining whether risktaking behavior changed in later blocks compared to earlier ones (practice trials were not included
in this analysis).
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Chapter 3: Results
Data from one male and four females were excluded because they were unable to complete the
entire testing protocol due to adverse side effects of the medication (nausea, fatigue, and
dizziness). The following analyses were all carried out at an alpha level of 0.05, and Bonferroni
corrections were used for post-hoc pairwise comparisons.
3.0 Demographics and questionnaires
Demographic data along with trait questionnaire scores and cognitive questionnaire scores are
shown in Table 1. The pramipexole and placebo groups did not show significant differences on
any of the variables (p > 0.05 for all variables; age t (38) = −0.84; education t (38) = −0.49; BDI
t (38) = 0.78; BAI t (38) = 0.50; SAS t (38) = 0.23; Happiness t (38) = −0.06; Sleepiness t (38) =
0.42; BIS t (38) = 1.00; Sensation Seeking Scale t (38) = −0.15; ANART t (38) = 0.14; MOCA
t (38) = 0.00; COWAT FAS t (38) = 0.46; COWAT Animal t (38) = − 0.14). This rules out any
pre-existing differences between the pramipexole and the placebo group on any of these
measures which might have affected performance on the impulsivity tasks, including age,
cognitive ability, trait impulsivity, and other potentially important variables.

Placebo

Pramipexole

Age

20.5 (1.3)

20.8 (0.9)

Gender

8 M; 12 F

8 M; 12 F

Handedness

18 R; 1 L; 1 Both

17 R; 2 L; 1 Both

Education

15.40 (1.05)

15.5 (0.89)

BDI

9.60 (7.18)

8.05 (5.26)
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BAI

8.60 (8.29)

7.45 (6.17)

SAS

11.50 (4.80)

11.20 (3.44)

Happiness

4.45 (0.58)

4.46 (0.64)

Sleepiness

10.05 (2.65)

9.60 (3.94)

BIS

62.05 (10.29)

58.60 (11.41)

Sensation Seeking
Scale

19.80 (5.72)

20.05 (4.47)

ANART

118.95 (6.46)

118.71 (4.44)

MOCA

27.80 (1.51)

27.80 (1.94)

COWAT FAS

40.15 (11.00)

38.60 (10.61)

COWAT Animals

24.55 (1.12)

24.80 (1.33)

Table 1: Demographic measures and questionnaire scores of the pramipexole and placebo
groups.

3.1 Physiological measures
Heart Rate - A 2 x 3 mixed measures ANOVA (Medication x Time) revealed a main effect of
Time [F (2, 74) = 32.40, MSe = 25.12, p < .001, Ƞ2 = .47]. As can be seen in Figure 4, this effect
is due to a decrease in HR from T1 to T2, and from T1 to T3 (both p < .001). There was also a
significant Medication x Time interaction [F (2, 74) = 4.37, MSe = 25.12, p= .016, Ƞ2 = .11]. The
difference in HR between T1 and T2, and T1 and T3 in the placebo group was 9.5 and 11.79,
respectively. The difference in HR between T1 and T2, and T1 and T3 in the pramipexole group
was 4.5 and 5.4, respectively. Thus, the differences between T1 and both T2 and T3 were larger
in the placebo group than in the pramipexole group. The main effect of Medication was not
significant [F (1, 36) = 0.084, p = .774], however, meaning that pramipexole had no effect on HR
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independently of the passage of time or the time of ingestion. Mauchly’s test of sphericity has not

Heart rate (pulse, beats/minute)

been violated.

Heart rate over time
80

Pramipexole
Placebo

75
70
65
60
T1

T2

T3

Time
Figure 4: Mean HR over time in the placebo and pramipexole groups. Error bars represent
SEM.

Blood pressure- Separate 2 x 3 repeated measures ANOVAs were conducted on diastolic and
systolic blood pressure. For diastolic blood pressure, Mauchly’s test indicated the assumption of
sphericity was not met [X2 (2) = 9.6, p = .008]. This was due to the variance of differences in both
groups in T3 - T2 being lower than in the other comparisons (i.e. T2 - T1 and T3 - T1). After
Huynh-Feldt corrections (ɛ = 0.81), there was a significant main effect of Time [F (1.74, 74) =
6.51, MSe = 28.68, p = .004, Ƞ2 = .123]. Post hoc Bonferroni corrected pairwise comparisons
revealed that this was due to diastolic blood pressure decreasing from T1 to T2 (p = .017), and
from T1 to T3 (p = .034), in both the pramipexole and the placebo group (see Figure 5). There was
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no main effect of Medication [F (1, 37) = 0.180, p = .674], and no Medication x Time interaction
[F (1.74, 74) = 0.500, p = 0.583]. These results indicate that participants in the pramipexole and
the placebo groups had higher diastolic blood pressure at the beginning of the testing session (T1)
than 2 hours later (T2) or at the end of the session (T3). Pramipexole did not change participants’
blood pressure readings in comparison to placebo.

Diastolic blood pressure (mmHg)

Diastolic blood pressure over time
Pramipexole

75

Placebo

70

65

60
T1

T2

T3

Time
Figure 5: Diastolic blood pressure over time in the placebo and pramipexole groups. Error
bars represent SEM.

For systolic blood pressure, Mauchly’s test also revealed a violation of the assumption of sphericity
due to the variance of differences in both groups in T3 - T2 being lower than in the other
comparisons. Due to the lower epsilon (ɛ = 0.67), and according to Girden (1992), a GreenhouseGeisser correction was applied and the effect of time was not significant [F (1.35, 74) = 3.54, p =
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.054]., The effect of Medication and the Medication x Time interaction were also not significant
(see Figure 6, all p’s > .05).

Systolic blood pressure (mmHg)

Systolic blood pressure over time
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Figure 6: Systolic blood pressure over time in the placebo and pramipexole groups. Error bars
represent SEM.

Mood ratings - The BL-VAS ratings across the time points in both groups were compared using a
2 x 3 repeated measures ANOVA. There was a significant effect of Time [F (2, 76) = 13.65, MSe
= 1748.37, p < .001, Ƞ2 = .264]. Bonferroni-corrected pairwise comparisons revealed this was due
to an overall decrease in alertness ratings from T1 to T2 (p = .001) and T2 to T3 (p < .001; see
Figure 7). This main effect was qualified by a Medication x Time interaction [F (2, 76) = 4.11,
MSe = 526.62, p = .020, Ƞ2 = 0.098]. This was due to the alertness scores significantly decreasing
from T1 to T2 and T1 to T3 in the pramipexole group (p’s < .001), but not in the placebo group (p
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= .84, and .31, respectively). The main effect of Medication was not significant [F (1, 38) = 2.63,
p = .113]. Mauchly’s test of sphericity has not been violated.
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(Alertness)
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Figure 7: Alertness ratings from the Bond-Lader Visual Analogue Scale over time in the placebo
and pramipexole groups. Error bars represent SEM.

3.2 Behavioral measures
3.2.1 Go/No-Go Task
Performance on the GNG for both groups, including accuracy and RT, is shown in Table 2. To
compare accuracy on the GNG between the placebo and pramipexole group, an independent
samples t-test was used. Levene’s test showed that variances were unequal between the groups; a
corrected value was used for the t-test, and revealed a significant difference between the groups,
t (28.3) = 2.72, p = .011, d = 0.86, with the pramipexole group having a lower accuracy. To further
explore whether this difference occurred due to errors on Go or on NoGo trials, separate t-tests
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were conducted on both accuracy measures. There was a significant difference in accuracy
between the placebo and pramipexole groups on Go trials [t (28.7) = 2.24, p = .033, d = 0.71,
corrected for unequal variances], with the pramipexole group having a lower accuracy than the
placebo group. The only error that is possible on a Go trial is timing out without making a response,
and as seen in Error! Reference source not found., the pramipexole group had twice as many t
imed-out Go trials as the placebo group, t (29.1) = 2.26, p = .031, d = 3.22. This is suggesting an
inhibition or stunting of a pre-potent and impulsive motor response in the pramipexole group. The
accuracy for NoGo trials was not significantly different between the placebo and pramipexole
groups, t (38) = 1.30, p = .20. To examine whether there might have been a general cognitive or
response slowing on the GNG, Go and NoGo trial RTs were compared between the placebo and
pramipexole groups using two tailed independent samples t-tests. There were no significant RT
differences between the groups in either Go [ t (38) = −0.574, p = 0.569] or NoGo [ t (38) = 1.315,
p = 0.196] trials. This rules out the explanation that the larger number of timeout Go trials in the
group that received pramipexole was due to a general cognitive slowing effect, as the RTs were
not significantly longer in the pramipexole group in either Go or NoGo trials. Thus, the inability
to respond in time on a Go trial was unique to the pramipexole group only, supporting our
hypothesis of decreased motor impulsivity in participants who received pramipexole.

Placebo

Pramipexole

0.94 (0.004)

0.91 (0.009)

0.96 (0.006)

0.93 (0.01)

Go RT

356.76 (26.23)

361.70 (28.17)

NoGo RT

487.19 (56.19)

470.28 (12.32)

Overall accuracy
Go accuracy

*
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Number of Go timeouts

*

6.8 (1.2)

12.5 (2.2)

Number of NoGo errors

8.3 (1.0)

9.3 (1.1)

SSRT

295.54 (32.16)

301.80 (34.32)

BART adjusted pump #

22.2 (2.7)

19.3 (1.1)

Table 2: Performance on the GNG, SST, and BART in the placebo and pramipexole groups.
Values are given as mean (SEM), * denotes p < .05.

3.2.2 Stop Signal Task
Participants in the placebo group had a successful inhibition rate of 40% (SD = 8%), and
participants in the pramipexole group had a rate of 39% (SD= 14%). An independent samples ttest revealed no significant difference between these rates, t (38) = 0.43, p = .67. The mean RT of
failed Stop trials was shorter than the mean RT of Go trials, [Failed Stop trial RT= 412 (118) ms,
Go trial RT = 456 (149) ms]. As a main measure of motor impulsivity, the SSRT for each
participant was calculated by taking the mean Go RT and subtracting the mean SSD. An
independent samples t-test was used to compare the SSRT of the two groups. The average SSRT,
which measures the Stop process RT, was compared between the placebo (M = 295.54, SEM =
32.16) and pramipexole (M = 301.80, SEM = 34.32) groups, and revealed no significant difference,
t (38) = 0.596, p = .555. Thus, the pramipexole and placebo groups did not take a significantly
different amount of time to complete the Stop process.

3.2.3 Balloon Analogue Risk Task
The adjusted average number of pumps, which is a measure of the participants’ riskiness and
tendency to continue pumping a balloon in anticipation of a larger reward, was compared between
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the placebo (M = 22.2, SEM = 2.7) and pramipexole (M = 19.3, SEM = 1.1) groups. There was no
significant difference between the groups on the adjusted average number of pumps, t (38) = 0.999,
p = .324, suggesting that pramipexole did not alter participants’ risk-taking in gambling-like
situations. The Medication x Block ANOVA on adjusted pumps revealed a main effect of Block,
F (2, 74) = 3.99, p = .022, MSe = 53.81 , Ƞ2 = . 098 (see Figure 8). Bonferroni corrected post-hoc
analyses revealed that the adjusted average number of pumps in Block 2 was significantly lower
than in Block 3. Block 1 did not significantly differ from Block 2 or Block 3. These findings
indicate that participants in both groups engaged in more risky-responding on the final block of
the task compared to the middle block. This could be a result of fatigue or increased confidence in
performance of the task. There was no significant main effect on Medication, or a

Adjusted average number of pumps

Medication x Block interaction. Mauchly’s test of sphericity has not been violated.

Adjusted average number of pumps in
each block of the BART
25

Placebo

Pramipexole

20

15

10
Block 1

Block 2

Block 3

Figure 8: Adjusted average number of pumps in each block of the BART for the placebo and
pramipexole groups. Error bars represent SEM.
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Chapter 4: Discussion
4.0 Summary of results
In the current study, young healthy participants were given a dose of the dopamine agonist
pramipexole, or a placebo, and then completed tasks measuring motor impulsivity and risk-taking.
We used three tasks to measure different aspects of impulsivity: the GNG task and the SST to
measure motor impulsivity, and the BART to measure risk-taking and gambling. Results indicated
that participants who received pramipexole had more timed out Go trials than the participants who
received placebo, but there were no RT differences in either Go or NoGo trials. This suggests
enhanced motor inhibition, thus evidence of decreased motor impulsivity in the pramipexole
group, which agrees with our proposed hypothesis and the literature. There was no significant
SSRT difference between the groups on the SST. Performance on the BART was also not different
between the placebo and the pramipexole groups, indicated by no difference in the adjusted
average number of pumps. These results align with the hypothesis that different aspects of
impulsivity might not be affected equally by dopamine agonists such as pramipexole.
4.1 Demographic, cognitive, and affective measures
Lack of differences between the groups on any of the demographic, cognitive, or affective
measures confirms that the randomization process produced groups similar in these important
characteristics. Particularly, there were no differences in pre-existing impulsivity, a factor which
has been shown to exacerbate the influence of dopaminergic medication on impulsivity
(Claassen et al., 2015; MacDonald et al., 2016). Therefore, because both groups were equivalent
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on these measures before drug administration and before the drug had time to take effect, results
on the behavioral tasks are not due to any pre-existing differences between the groups.
4.2 Physiological changes
As the experiment progressed, participants showed a decrease in HR and in alertness scores on
the BL-VAS. Because there was no main effect of medication on these measures, we interpret
these decreases as being a result of participants becoming more comfortable with the
experimental setting, and being seated and inactive for nearly 3 hours. The Medication x Time
interaction indicates that participants who received pramipexole had greater differences in BLVAS ratings from T1 to T2 and T3 than those who received placebo. Nevertheless, even at T3,
when scores were lowest, the pramipexole participants’ average scores on the BL-VAS centered
around ‘Neutral’, indicating they were not feeling particularly tired or sleepy. Additionally, the
equivalent RTs between the placebo and pramipexole groups mean that this decrease in alertness
did not affect RTs and that our finding of more timed out Go trials in the pramipexole group is
not simply due to a decrease in alertness.
4.3 Motor impulsivity
Our findings suggest that pramipexole does not increase motor impulsivity, and might in fact
decrease it, in line with other experiments that find either unchanged or decreased motor
impulsivity after administration of dopamine agonists (Caillava-Santos et al., 2015; Fera et al.,
2007; Hiebert et al., 2014; Müller, Benz, & Börnke, 2001; Müller, Benz, & Przuntek, 2002;
Nandam et al., 2013; van Wouwe et al., 2016). It is important to note that participants on
pramipexole had more timed out Go trials than those who received placebo, but did not have
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longer RTs on the GNG task, or on the other tasks. Thus, it is unlikely that the higher number of
timed out trials is simply due to an overall slowing effect or a motor impairment due to
pramipexole. Rather, they seemed to have imposed a slightly more conservative criterion for
responding in the Go trials (i.e., less motor impulsivity). This pattern suggests that participants
on pramipexole were in fact exhibiting a decrease in impulsive behavior.

There was no corresponding difference between the placebo and pramipexole groups in the
number of commission errors on NoGo trials, as would have been predicted if pramipexole
improves motor impulsivity. It is possible that we did not find fewer commission errors for the
pramipexole relative to the placebo group because of our 3:1 ratio of Go:NoGo trials, meaning
there were far fewer NoGo trials and therefore less power to detect subtle differences across
groups owing to medication in the NoGo condition. Indeed, there were very few NoGo errors
overall in either group. We used the chosen ratio to ensure the development of a pre-potent Go
response (Boucher et al., 2012; Kiehl et al., 2000; Petit et al., 2012; Rubia et al., 2001) that
would engender an impulsive motor action in the NoGo condition. In future studies, more blocks
and hence trials overall would be advisable. Alternatively, a different ratio of Go:NoGo trials
might be considered though the latter approach could result in a failure to induce the pre-potent
motor response.

The experiment by Hamidovic and colleagues (2008) showed that pramipexole did not have an
effect on GNG performance in healthy controls, whereas we found more timed out Go trials.
This discrepancy may be due to differences between the GNG tasks used. Hamidovic and
colleagues employed a more complex GNG task, with four stimuli corresponding to Go
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responses and four corresponding to NoGo responses. This complexity and the need to remember
stimulus-response associations in addition to executing motor responses or inhibiting them
confounds motor impulsivity and working memory, potentially accounting for the differences in
their findings. They also used a 1:1 ratio of Go:NoGo trials. In using one Go and one NoGo
stimulus in our task, and employing a 3:1 ratio of Go:NoGo trials, we ensured that the task
measured motor impulsivity more clearly and promoted the development of a pre-potent motor
response. Additionally, due to the small sample size in their study (N=10), they were potentially
underpowered to detect subtle medication effects on impulsivity.

Although we could not find any other studies that have investigated the effect of pramipexole on
GNG performance in healthy controls, a few similar studies have been conducted with PD
patients on and off medication (Antonelli et al., 2014; Farid et al., 2009; Herz et al., 2014). In a
small positron emission tomography study (N = 7) of PD patients performing a GNG and a
delayed discounting task on and off pramipexole, Antonelli and colleagues (2014) found no
influence of pramipexole on RT or errors on the GNG. A functional magnetic resonance imaging
(fMRI) study by Farid and colleagues (2009), tested PD patients (N = 9) on and off levodopa in
contrast with healthy controls and found that there was no medication effect on GNG
performance. Herz and colleagues (2014) also found no medication effects on performance of a
more complex GNG task in an fMRI study of 13 PD patients with dyskinesia and 13 without
dyskinesia, tested on and off their regular dopaminergic medication. The GNG task consisted of
three stimuli, thus it was more complex and less likely to elicit pre-potent responses. The few
experiments that investigated the effects of dopaminergic medication on GNG performance in
PD patients found no behavioral differences between patients on and off medication. However,
44

all the studies tested only a small sample of participants, and were very likely underpowered to
detect medication effects. Further, the use of complex tasks and less emphasis on inducing a prepotent motor response could have undermined these studies.

Another task commonly used to measure motor inhibition is the SST (Bedard et al., 2002; Eagle,
Baunez, et al., 2008; Williams et al., 1999). We did not find SSRT differences on the SST
between the placebo and pramipexole groups. Indeed, results from the SST and the GNG task do
not always correspond and a PCA has shown the two tasks load on different factors (Caswell et
al., 2015). The tasks, although similar, reflect different inhibitory processes. Schachar and
colleagues, (2007) proposed a distinction between ‘motor restraint’ and ‘motor cancellation’.
The SSRT measures the time taken to complete a ‘stopping’ process once an action has already
been selected and initiated (Dalley et al., 2011; Winstanley, 2011). In this way, it is measuring
‘motor cancellation’. This is different from the motor inhibition process in the GNG, which
measures the ability to inhibit the initiation of a response (Dalley et al., 2011; Eagle, Baunez, et
al., 2008; Reynolds, Penfold, & Patak, 2008; Winstanley, 2011; Winstanley et al., 2010). This
process is therefore one of ‘motor restraint’. The two processes elicited by these tasks have also
been shown to have distinct neural activation patterns and dissociable pharmacology (Eagle,
Bari, & Robbins, 2008; Rubia et al., 2001).

We are aware of only three studies that investigated the effects of dopaminergic medication on
SST performance in healthy controls. Farr and colleagues, (2014) gave 25 healthy controls a
single dose of the dopamine reuptake inhibitor methylphenidate (45 mg) and asked them to
complete the SST while placed in an fMRI scanner. Data from these participants was compared
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to a demographically-matched sample of participants who did not receive any drugs but
completed the task in a different experiment. Results indicated that methylphenidate did not
affect any behavioral measures of performance on the SST. A within-subjects, placebocontrolled study by Costa and colleagues, (2013) tested 54 healthy controls on placebo and on
methylphenidate. They found no differences in SST performance between participants whether
they received methylphenidate or a placebo. Another within-subjects placebo controlled
experiment by Nandam and colleagues (2013) examined the effects of a single dose of the
dopamine agonist cabergoline (1.25 mg) on SST performance in healthy controls. Participants
showed a faster SSRT on cabergoline compared to placebo, suggesting that cabergoline
improved impulse control by speeding up the stopping process of the SST. However, the version
of the task employed in this experiment contained a high number of trials (512) in comparison to
the task employed in other experiments (e.g. 234 trials in Costa et al., 2013). Thus it is possible
that the effects of dopaminergic medication on SST are very small and can only be detected with
a very large number of trials. Additionally, cabergoline is a D2 agonist, whereas methylphenidate
acts through a different mechanism, by blocking the reuptake of dopamine from the synapse.
Based on the findings of these studies, it appears that SST performance is not very sensitive to
dopaminergic drugs, which would be in line with the pattern of findings in our study.

Studies of PD patients on and off dopaminergic medication also suggest that there is little
influence on SST performance. Obeso, Wilkinson, and Jahanshahi, (2011) tested 17 patients with
PD in two sessions, one on and one off levodopa. They found no differences on any measure of
SST between on and off sessions. Claassen and colleagues (2015), tested 24 patients with PD on
and off dopamine agonists (although half the sample was also on concomitant levodopa
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treatment). The PD group was split based on the presence of ICDs (12 PD with ICD, 12 without
ICD). The authors found no difference in performance on the SST between sessions on and off
dopaminergic medication. From the limited number of studies that have looked at the effects of
dopaminergic drugs on performance of the SST, it seems likely that if there is any effect on
SSRT and thus impulse control, it is a very small effect that requires a large number of trials to
uncover. Thus, one potential explanation for the null results of the SST in our study is that our
version of the task did not contain enough trials to detect such a small change.
4.4 Cognitive impulsivity
Cognitive impulsivity, although related to motor impulsivity, is certainly distinct from it. We
used the BART to measure cognitive impulsivity, specifically risk-taking and gambling-like
behaviour. In our experiment, we found no differences between participants who received
pramipexole and those who received placebo on the BART. Claassen and colleagues, (2011)
aimed to examine the effects of dopaminergic medication on risk-taking in PD patients with
ICDs (N= 22) and without ICDs (N=19). They found that in the PD without ICD group, there
was no difference in risk-taking on the BART between the on and off medication testing
sessions. However, in the PD with ICD group, there was evidence of increased risk-taking in the
session on medication compared to off medication. Thus, dopaminergic medication alone did not
increase risk taking. In another study, Simioni, Dagher and Fellows, (2012) tested 23 PD
patients on and off dopaminergic medication. They found that although medication had no
overall effect on risk-taking on the BART, it did increase risk-taking across the 3 blocks of the
BART. That is, PD patients increased the number of pumps from the 1st to the 3rd block of the
BART when tested on medication more than they did when tested off medication. These results

47

suggest that medication effects on risk-taking are more subtle and might require some time
before they influence behavior. Finally, a study by MacDonald and colleagues (2016)
specifically tested the hypothesis that medication effects on risk-taking are dependent on initial
dopamine levels and predisposition for risky behavior using gene polymorphisms in older
healthy controls (N=28). Over three testing sessions, participants received ropinirole (0.5 or 1.0
mg) or placebo. Using mixed-model linear regression, they found that controls with a high basal
dopamine neurotransmission (measured through gene polymorphisms) exhibited more risktaking behavior on ropinirole versus placebo, only following negative but not positive
reinforcement (i.e. trials on which the balloon popped versus trials they cashed out). The pattern
of findings above indicates that dopamine agonists’ effects on risk-taking are dependent on
initial predisposition to risky behavior and impulsivity (measured either through clinical
assessments or gene polymorphisms). Thus, dopaminergic medication alone is not sufficient to
lead to more impulsivity and risk-taking.
4.5 Limitations
In this study, conducted with healthy volunteers, participants received a single dose of a
dopamine agonist. The dose (0.5 mg) was not as large as the dose prescribed to clinical
populations, because dopamine agonist dosage needs to be increased gradually over a longer
period of time to avoid side effects. Studies that have found an association between dopamine
agonist use and ICDs (Cools, Barker, Sahakian, & Robbins, 2003; Pontone et al., 2006;
Weintraub et al., 2010) have all been conducted in clinical populations, with patients who have
been treated with dopaminergic medication for a long duration. The current study was not
longitudinal so it was impossible to examine any long-term effects of pramipexole. Additionally,
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we could not safely administer a higher dose of the drug, and this was the dosage commonly
used in other studies that administered pramipexole to healthy participants (Hamidovic et al.,
2008; Pizzagalli et al., 2008; Riba et al., 2008). Administering a larger dose would most likely
increase the occurrence of adverse effects that lead to participant drop-out. Thus, it is possible
that a single (and comparatively low) dose of pramipexole administered to healthy controls does
not have enough potency to effect the changes that lead to ICDs and increased risk-reward
impulsivity. Pramipexole’s effects on impulsive behaviors may need time to build up, and such
effects were not investigated in this study.

It is important to note that out of the four participants whose data was discarded, three were
females, who had a lower body mass index than the one male. Other studies of healthy controls
that administered pramipexole either excluded females (Riba et al., 2008; Samuels, Hou,
Langley, Szabadi, & Bradshaw, 2006; Samuels, Hou, Langley, Szabadi, & Bradshaw, 2007; Ye
et al., 2011) or excluded participants below a certain body mass index (Hamidovic et al., 2008;
Pizzagalli et al., 2008; Santesso et al., 2009). We chose to include all participants in our study to
increase generalizability, however, future studies need to weight generalizability versus the
chance of participant drop-out.

Additionally, in our study we were not able to analyze results based on our participants’
predisposition to, or presence of, impulsive behavior, because all participants scored similarly on
the baseline impulsivity measures. Other studies may wish to look at gene polymorphisms in
young healthy controls as a moderating variable of the effect of dopaminergic medication on
impulsivity.
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Finally, it is important to note that participant performance on the SST in this experiment was
such that appropriate analysis of the SST was not possible. One of the conditions that needs to be
met for a proper interpretation of the SST is that participant accuracy is approximately 50%. In
our experiment, the average accuracy was around 40%, suggesting that participants either did not
understand the instructions, or that there were not enough trials for participants to develop
competency with the task. Thus, it is possible that the results of the SST would be different in
our study given more SST trials.
4.6 Conclusion
Dopamine agonists are commonly prescribed to treat the motor symptoms of PD, RLS, as well as
some cases of mood disorders, and addiction treatments. Studies have found an association
between dopaminergic medication and ICDs in patients with PD, suggesting that dopamine
agonists may increase impulsive behavior. At the same time, experiments directly investigating
the effects of dopaminergic medication on impulsivity measures found a decrease in impulsivity
after dopaminergic medication. The current study hypothesized that dopamine agonists decrease
some aspects of impulsivity, particularly motor impulsivity, and may increase other aspects of
impulsivity, such as risk-taking and gambling. To test this hypothesis, healthy young adults were
given pramipexole, or a placebo pill, and asked to perform tasks measuring impulsivity. The
three chosen tasks were the GNG and the SST to measure motor impulsivity, and the BART to
measure risk-taking and gambling.
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Participants who received pramipexole had more timed-out Go trials on the GNG than those who
received placebo. This is supporting the proposed hypothesis that pramipexole decreases motor
impulsivity and in fact leads to a delayed response compared to controls who received placebo.
There was no difference between the two groups in the SST, which is possibly due to differential
effects of pramipexole on motor cancellation (as in the SST) as opposed to motor restraint (as in
the GNG), and also due to conditions not being met for appropriate analysis. On the BART, there
was also no difference between the pramipexole and the placebo groups. Similar studies have
found that dopaminergic medication effects on the BART are moderated by a predisposition to
impulsivity as measured by gene polymorphisms. Therefore, it is likely pramipexole decreases
some aspects of motor impulsivity such as action restraint, and may also increase other aspects of
impulsivity such as risk taking, if there is a predisposition for such behavior.
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Appendix III: Pramipexole safety screening questionnaire
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Appendix IV: Bond-Lader Visual Analogue Scale
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Appendix V: American National Adult Reading Test wordlist

1. ache

23. papyrus

45. caprice

2. debt

24. asthma

46. demesne

3. pint

25. hiatus

47. imbroglio

4. depot

26. simile

48. hyperbole

5. chord

27. blatant

49. syncope

6. bouquet

28. cellist

50. prelate

7. deny

29. zealot

8. capon

30. abstemious

9. heir

31. meringue

10. aisle

32. placebo

11. subtle

33. façade

12. nausea

34. pugilist
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13. gauge

35. virulent

14. naïve

36. worsted

15. thyme

37. détente

16. courteous

38. anise

17. algae

39. sieve

18. fetal

40. chassis

19. quadruped

41. beatify

20. epitome

42. scion

21. superfluous

43. cabal

22. chamois

44. apropos
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Appendix VIII: Barratt Impulsiveness Scale
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Appendix IX: Sensation Seeking Scale
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Appendix X: Epworth Sleepiness Scale
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Appendix XI: Oxford Happiness Questionnaire
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Appendix XII: Beck’s Depression Inventory
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Appendix XIII: Beck Anxiety Inventory
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